Edition:
United States

Profile: AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

3.68USD
23 Sep 2016
Change (% chg)

$0.10 (+2.79%)
Prev Close
$3.58
Open
$3.69
Day's High
$3.73
Day's Low
$3.62
Volume
224,684
Avg. Vol
363,389
52-wk High
$5.88
52-wk Low
$2.40

AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04 and Zalviso, which utilizes sublingual sufentanil, delivered through a non-invasive route of administration. The Company's product candidate pipeline also includes ARX-03, which is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

ARX-04

The Company's product candidate, ARX-04 is an investigational product candidate consisting of a single 30 mcg sufentanil sublingual tablet delivered through a disposable, pre-filled, single-dose applicator (SDA). The Company is developing ARX-04 for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. ARX-04 has completed Phase II clinical trials.

Zalviso

The Company's Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets, 15 micrograms, delivered by the Zalviso System, a needle-free, patient-administered, pain management system, or together, Zalviso. Zalviso is designed to help address certain problems associated with post-operative intravenous patient-controlled analgesia (IV PCA). The Company has completed Phase III clinical trials for Zalviso.

ARX-03

The Company's ARX-03 is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. The Company has completed Phase II clinical trials for ARX-03.

The Company competes with Pfizer, Inc., CareFusion Corporation, Baxter International Inc., Curlin Medical, Inc., Smiths Medical, Cara Therapeutics, Inc., Trevena, Inc., Recro Pharma, Inc. and Innocoll AG.

Company Address

AcelRx Pharmaceuticals Inc

351 Galveston Dr
REDWOOD CITY   CA   94063-4736
P: +1650.2163500
F: +1650.2166500

Company Web Links